Search

Ervex 150

Ervex 150

erlotinib

Manufacturer:

Vexxa Lifesciences

Distributor:

VE Pharma
Concise Prescribing Info
Contents
Erlotinib
Indications/Uses
Treatment of locally advanced or metastatic non-small cell lung cancer after failure of at least 1 prior chemotherapy regimen.
Click to view Ervex 150 detailed prescribing information
Dosage/Direction for Use
Non-small cell lung cancer 150 mg daily. Pancreatic cancer 100 mg daily. May reduce dose in 50-mg steps if necessary. Max: 450 mg when used w/ rifampicin.
Click to view Ervex 150 detailed prescribing information
Overdosage
View Ervex 150 overdosage for action to be taken in the event of an overdose.
Administration
Should be taken on an empty stomach: Take at least 1 hr before or 2 hr after meals.
Contraindications
Hypersensitivity.
Click to view Ervex 150 detailed prescribing information
Warnings
For additional cautionary notes to warn of the potential risk of using the medicine... Click to view Ervex 150 detailed prescribing information
Special Precautions
Interstitial lung disease-like events including fatalities; MI/ischemia; CVA; microangiopathic hemolytic anemia w/ thrombocytopenia. Periodic liver function tests (transaminases, bilirubin, & alkaline phosphatase). Hepatic impairment. Not recommended in severe renal impairment; CrCl <15 mL/min or serum creatinine conc >1.5 times the ULN. Pregnancy.
Click to view Ervex 150 detailed prescribing information
Adverse Reactions
Rash & diarrhea. GI disturbances, GI bleeding, fatigue, alopecia, stomatitis, pruritus, dry skin, paronychia, conjunctivitis, keratoconjunctivitis sicca, epistaxis & abdominal pain; alteration in liver function tests.
Click to view Ervex 150 detailed prescribing information
Drug Interactions
Increased conc & toxicity w/ CYP450 isoenzyme CYP3A4 inhibitors eg, ketoconazole. Reduced conc & efficacy w/ CYP3A4 inducers eg, rifampicin. Increased exposure w/ ciprofloxacin or potent inhibitors of CYP1A2. Altered distribution or elimination w/ ciclosporin & verapamil. Impaired absorption w/ antacids, proton pump inhibitors, or H2-receptor antagonists. Reduced exposure in smokers.
Click to view Ervex 150 detailed prescribing information
Storage
View Ervex 150 storage conditions for details to ensure optimal shelf-life.
Description
View Ervex 150 description for details of the chemical structure and excipients (inactive components).
Action
View Ervex 150 mechanism of action for pharmacodynamics and pharmacokinetics details.
MIMS Class
Targeted Cancer Therapy
ATC Classification
L01EB02 - erlotinib ; Belongs to the class of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors. Used in the treatment of cancer.
Presentation/Packing
Form
Ervex 150 FC tab 150 mg
Packing/Price
30's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in